Provided by Tiger Trade Technology Pte. Ltd.

Cytokinetics

64.64
+2.133.41%
Post-market: 63.22-1.4174-2.19%19:10 EST
Volume:2.54M
Turnover:159.28M
Market Cap:7.90B
PE:-10.23
High:65.25
Open:62.36
Low:60.30
Close:62.51
52wk High:70.98
52wk Low:29.31
Shares:122.26M
Float Shares:119.09M
Volume Ratio:1.13
T/O Rate:2.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3179
EPS(LYR):-5.2646
ROE:-572.15%
ROA:-24.93%
PB:-15.17
PE(LYR):-12.28

Loading ...

Cytokinetics Grants Stock Options and RSUs to New Employees

Reuters
·
Dec 17, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
Dec 17, 2025

BRIEF-EMA's CHMP Recommended Granting Marketing Authorisation For Moderna's Mnexspike

Reuters
·
Dec 12, 2025

Cytokinetics Says EU Committee Recommends Marketing Authorization for Myqorzo

MT Newswires Live
·
Dec 12, 2025

Cytokinetics Wins CHMP Backing for MYQORZO in Obstructive Hypertrophic Cardiomyopathy

Reuters
·
Dec 12, 2025

Cytokinetics Announces Positive Chmp Opinion of Myqorzo® (Aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
Dec 12, 2025

Cytokinetics Price Target Maintained With a $72.00/Share by Needham

Dow Jones
·
Dec 12, 2025

Cytokinetics EVP and Chief Commercial Officer Andrew Callos Reports Disposal of Common Shares

Reuters
·
Dec 09, 2025

Cytokinetics EVP Fady Ibraham Malik Reports Disposal of Common Shares

Reuters
·
Dec 03, 2025

Director Robert Arthur Harrington Sells Cytokinetics Incorporated Common Shares

Reuters
·
Dec 02, 2025

The Bull Case For Cytokinetics (CYTK) Could Change Following Legal Scrutiny Into FDA Filings for Aficamten

Simply Wall St.
·
Nov 30, 2025

Promising Prospects for Cytokinetics’ Aficamten in oHCM and nHCM Markets

TIPRANKS
·
Nov 25, 2025

Did Positive Aficamten Trial Results Just Shift Cytokinetics' (CYTK) Investment Narrative?

Simply Wall St.
·
Nov 22, 2025

Cytokinetics Director Lynne Parshall Reports Sale of Common Shares

Reuters
·
Nov 20, 2025

EVP Research & Development Fady Ibraham Malik Reports Disposal of Cytokinetics Common Shares

Reuters
·
Nov 19, 2025

Cytokinetics Grants Stock Options and RSUs as Employment Inducements

Reuters
·
Nov 19, 2025

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

GlobeNewswire
·
Nov 19, 2025

BRIEF-Cytokinetics Supports American Heart Association Initiative To Improve Care For People Living With Hypertrophic Cardiomyopathy

Reuters
·
Nov 17, 2025

Cytokinetics Supports American Heart Association Initiative to Improve Care for People Living With Hypertrophic Cardiomyopathy

THOMSON REUTERS
·
Nov 17, 2025

Cytokinetics Files Initial Beneficial Ownership Statement for Chief Legal & Admin Officer Jeffrey Hessekiel

Reuters
·
Nov 15, 2025